Alembic Pharma Invests 45% in Canadian JV

Key Transaction Details

• Date of Disclosure: 6th June, 2026
• Parties Involved: Alembic Pharmaceuticals Limited, Difgen Holdings LLC, and Mr. Sukhad Juneja (collectively referred to as "parties")
• Investment Target: 17989377 Canada Inc. (the "Canadian Corporation")
• Company's Equity Stake: 45% in the Canadian Corporation

Ownership Structure

The shareholding of the Canadian Corporation will be distributed as follows:

• Alembic Pharmaceuticals Limited: 45%
• Difgen Holdings LLC: 45%
• Others (including Mr. Sukhad Juneja): 10%

Purpose and Business Focus

The investment is intended to establish a platform for development, commercialization, distribution, and marketing of pharmaceutical products focused specifically on the Canadian market.

Governance and Rights

The board of directors of the Canadian Corporation comprises nominee directors of the shareholders along with an independent director. The agreement provides for customary shareholder rights including participation in key decision matters.

Related Party Status

The parties to the Joint Venture are not related to the promoter/promoter group/group company of Alembic Pharmaceuticals in any manner. The investment does not fall within the purview of Related Party Transaction for the Company.